Syneron Bio Partners with AstraZeneca in Potential $3.4 Billion Deal
Deal News | Apr 23, 2025 | Goodwin
Syneron Bio, a biotech firm focused on developing macrocyclic peptide therapeutics, has entered a strategic collaboration with AstraZeneca. The partnership aims to leverage Syneron Bio's Synova platform, which supports the advancement of drugs targeting chronic diseases. AstraZeneca will pay Syneron Bio an initial $75 million and may contribute up to an additional $3.4 billion in milestone payments as the collaboration progresses. Renowned law firm Goodwin assisted Syneron Bio in this transaction. Syneron Bio plans to use the proceeds to expand its R&D center in Beijing. The collaboration signals a significant step for both companies in pioneering treatments for rare, autoimmune, and metabolic diseases.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital
Geography
- China – Syneron Bio plans to expand its research and development center in Beijing.
- Global – AstraZeneca operates globally and the collaboration with Syneron Bio impacts international markets.
Industry
- Biotechnology – The article discusses a biotech company, Syneron Bio, that focuses on developing macrocyclic peptide therapeutics.
- Pharmaceuticals – AstraZeneca, a global pharmaceutical company, is collaborating with Syneron Bio to develop treatments for chronic diseases.
- Venture Capital – Syneron Bio has completed multiple rounds of equity financing backed by venture capital funds, highlighting the role of venture capital in its operations.
Financials
- 75,000,000 – Upfront payments by AstraZeneca to Syneron Bio.
- 3,400,000,000 – Potential development and commercial milestone payments by AstraZeneca.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Syneron Bio | Target | Company | A biotechnology company focused on macrocyclic peptide therapeutics. |
| AstraZeneca | Bidding Company | Company | A pharmaceutical giant entering a collaboration with Syneron Bio. |
| Goodwin | Legal Advisor | Company | Global law firm advising Syneron Bio on the strategic collaboration. |
| Wenseng Wendy Pan | Lead Legal Advisor | Person | Led the Goodwin legal team advising Syneron Bio. |